Literature DB >> 20697731

Utility analysis of disability caused by amblyopia and/or strabismus in a population-based, historic cohort.

Elizabeth S van de Graaf1, Hanneke van Kempen-du Saar, Caspar W N Looman, Huib J Simonsz.   

Abstract

BACKGROUND: Amblyopia (prevalence 3.4%) is in principle treatable, but approximately one quarter of children do not reach reading acuity in the amblyopic eye. Adults with persistent amblyopia and/or strabismus experience a decrease in quality of life. This was now quantified by patient-perceived utility values.
METHODS: Subjects were born 1962-1972 and had been treated by occlusion therapy for amblyopia by one orthoptist 30-35 years ago. All children in Waterland with amblyopia and/or strabismus had been referred to this orthoptist. Utilities were derived by methods of time trade-off, TTO (lifetime traded against perfect vision) and standard gamble, SG (death risk accepted for perfect vision). Most troubling eye disorder (low acuity of the amblyopic eye, lacking stereopsis or strabismus) was chosen and ranked among nine chronic disorders according to the subject's perceived severity.
RESULTS: From 201 patients that could be contacted 35 years after occlusion therapy--out of 471 who had been occluded--135 were included: 17 could not be reached, 34 refused, and 15 had other reasons to not participate. Mean age was 40.86 years; 53% were male. Seventy percent were willing to trade lifetime according to the TTO method; its mean (log) utility was 0.963, i.e., a decrease in quality of life of 3.7%. Thirty-seven percent accepted death risk according to the SG method; its mean utility was 0.9996. TTO outcomes correlated with current near and distance visual acuity. Low acuity of the amblyopic eye, chosen as most troubling eye disorder, ranked slightly less severe than tooth decay.
CONCLUSION: Amblyopia and/or strabismus patients had a slightly decreased utility. The decrease is small but still important in the cost-effectiveness of vision screening because these conditions occur very frequently.

Entities:  

Mesh:

Year:  2010        PMID: 20697731      PMCID: PMC2974182          DOI: 10.1007/s00417-010-1457-z

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  10 in total

1.  [Evaluation of visual acuity in a historical cohort of 137 patients treated for amblyopia by occlusion 30-35 years ago].

Authors:  B Simonsz-Tóth; S E Loudon; H van Kempen-du Saar; E S van de Graaf; J H Groenewoud; H J Simonsz
Journal:  Klin Monbl Augenheilkd       Date:  2007-01       Impact factor: 0.700

2.  Risk of bilateral visual impairment in individuals with amblyopia: the Rotterdam study.

Authors:  Redmer van Leeuwen; Marinus J C Eijkemans; Johannes R Vingerling; Albert Hofman; Paulus T V M de Jong; Huib J Simonsz
Journal:  Br J Ophthalmol       Date:  2007-05-23       Impact factor: 4.638

3.  The burden of amblyopia and strabismus: justification of treatment and screening revisited.

Authors:  Josefin Nilsson
Journal:  Arch Ophthalmol       Date:  2008-01

4.  Chronic amblyopia and strabismus in children.

Authors:  George R Beauchamp
Journal:  Arch Ophthalmol       Date:  2007-06

5.  The comparability and reliability of five health-state valuation methods.

Authors:  P F Krabbe; M L Essink-Bot; G J Bonsel
Journal:  Soc Sci Med       Date:  1997-12       Impact factor: 4.634

6.  Quality of life associated with visual loss: a time tradeoff utility analysis comparison with medical health states.

Authors:  Melissa M Brown; Gary C Brown; Sanjay Sharma; Brandon Busbee
Journal:  Ophthalmology       Date:  2003-06       Impact factor: 12.079

7.  Amblyopia & Strabismus Questionnaire: design and initial validation.

Authors:  E S van de Graaf; G W van der Sterre; J R Polling; H van Kempen; B Simonsz; H J Simonsz
Journal:  Strabismus       Date:  2004-09

8.  Does amblyopia affect educational, health, and social outcomes? Findings from 1958 British birth cohort.

Authors:  J S Rahi; P M Cumberland; C S Peckham
Journal:  BMJ       Date:  2006-03-06

9.  Amblyopia and Strabismus Questionnaire (A&SQ): clinical validation in a historic cohort.

Authors:  Elizabeth S van de Graaf; Geertje W van der Sterre; Hanneke van Kempen-du Saar; Brigitte Simonsz; Caspar W N Looman; Huib J Simonsz
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-06-05       Impact factor: 3.117

10.  Construct validation of the Amblyopia and Strabismus Questionnaire (A&SQ) by factor analysis.

Authors:  Elizabeth S van de Graaf; Joost Felius; Hanneke van Kempen-du Saar; Casper W N Looman; Jan Passchier; Henk Kelderman; Huibert J Simonsz
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-06-03       Impact factor: 3.117

  10 in total
  5 in total

1.  Pediatric intracranial arachnoid cysts: comparative effectiveness of surgical treatment options.

Authors:  Zarina S Ali; Shih-Shan Lang; Dara Bakar; Phillip B Storm; Sherman C Stein
Journal:  Childs Nerv Syst       Date:  2013-10-27       Impact factor: 1.475

2.  Microvascular Decompression Versus Stereotactic Radiosurgery for Trigeminal Neuralgia: A Decision Analysis.

Authors:  Ian Berger; Nikhil Nayak; James Schuster; John Lee; Sherman Stein; Neil R Malhotra
Journal:  Cureus       Date:  2017-01-26

3.  The cost-effectiveness of different visual acuity screening strategies in three European countries: A microsimulation study.

Authors:  Eveline A M Heijnsdijk; Mirjam L Verkleij; Jill Carlton; Anna M Horwood; Maria Fronius; Jan Kik; Frea Sloot; Cristina Vladutiu; Huibert J Simonsz; Harry J de Koning
Journal:  Prev Med Rep       Date:  2022-06-27

4.  Patient-reported utilities in bilateral visual impairment from amblyopia and age-related macular degeneration.

Authors:  Elizabeth S van de Graaf; Dominiek D G Despriet; Caroline C W Klaver; Huibert J Simonsz
Journal:  BMC Ophthalmol       Date:  2016-05-17       Impact factor: 2.209

5.  Quality of life during occlusion therapy for amblyopia from the perspective of the children and from that of their parents, as proxy.

Authors:  Geertje W van der Sterre; Elizabeth S van de Graaf; Helma M van der Meulen-Schot; Ellen Abma-Bustraan; Henk Kelderman; Huibert J Simonsz
Journal:  BMC Ophthalmol       Date:  2022-03-25       Impact factor: 2.086

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.